XBIO 最新10-Q变化
将 XBIO 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-06 与上一份 10-Q · 2026-05-12
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +66 | −5 | ~19 | 48 |
| 市场风险(第3项) | 文字有新增/删除 | +115 | 0 | ~5 | 12 |
| 控制与程序 | 文字有新增/删除 | +116 | 0 | ~5 | 11 |
| 法律诉讼 | 文字有新增/删除 | +119 | 0 | ~4 | 9 |
| 风险因素 | 公司称无重大变化(指向 10-K) | — | — | — | — |
| 其他信息 | 文字有新增/删除 | +122 | −1 | ~3 | 6 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-06
Item 3 Quantitative and Qualitative Disclosures About Market Risk 22
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 23
Accrued expenses and other current liabilities 572,440 709,916
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
相对上期删除的文字 · 来源:10-Q · 2026-05-12
In some cases, these statements may be identified by terminology such as “may,” “will,” “would,” “could,” “should,” “expect,” “plan,”
“anticipate,” “believe,” “estimate,” “seek,” “approximately,” “intend,” “predict,” “potential,” “projects,” “upcoming”, “opportunity”, “target” or “continue,” or the negative of such terms and other comparable terminology. Although we believe that the expectations reflected in the forward-looking st…
We incurred a net loss of approximately $456,000 for the three months ended March 31, 2026. We had an accumulated deficit of approximately $200.3 million at March 31, 2026, as compared to an accumulated deficit of approximately $199.9 million at December 31, 2025. Working capital was approximately $…
Our principal source of liquidity consists of cash. At March 31, 2026, we had approximately $7.3 million in cash and $1.0 million in current liabilities. At December 31, 2025, we had approximately $7.9 million in cash and $1.0 million in current liabilities. We have historically relied upon sales of…
Cash flows used in operating activities for the three months ended March 31, 2026 totaled approximately $0.5 million, which was primarily due to our net loss for the period and, to a lesser extent, a decrease in accounts payable, accrued expenses and other liabilities. Cash flows used in operating a…
市场风险(第3项)
相对上期新增的文字 · 来源:10-Q · 2026-08-06
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 23
Accrued expenses and other current liabilities 572,440 709,916
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Issuance of common stock in connection with restricted stock – – 7,000 7 (7) – – – –
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-08-06
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 23
Accrued expenses and other current liabilities 572,440 709,916
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Issuance of common stock in connection with restricted stock – – 7,000 7 (7) – – – –
法律诉讼
相对上期新增的文字 · 来源:10-Q · 2026-08-06
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 23
Accrued expenses and other current liabilities 572,440 709,916
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Issuance of common stock in connection with restricted stock – – 7,000 7 (7) – – – –
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-08-06
Accrued expenses and other current liabilities 572,440 709,916
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Issuance of common stock in connection with restricted stock – – 7,000 7 (7) – – – –
Issuance of common stock in connection with restricted stock – – 7,000 7 (7) – – – –
相对上期删除的文字 · 来源:10-Q · 2026-05-12
During the quarter ended March 31, 2026, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议